Biohaven Ltd. (NYSE:BHVN) Stake Boosted by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC boosted its stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 2,952.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,180 shares of the company's stock after buying an additional 11,781 shares during the quarter. Tower Research Capital LLC TRC's holdings in Biohaven were worth $455,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in BHVN. JPMorgan Chase & Co. grew its holdings in Biohaven by 144.5% during the 4th quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company's stock valued at $73,922,000 after buying an additional 1,169,721 shares during the last quarter. Norges Bank acquired a new stake in shares of Biohaven during the fourth quarter valued at $33,711,000. Vanguard Group Inc. raised its stake in Biohaven by 8.1% in the 4th quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company's stock valued at $314,267,000 after purchasing an additional 628,211 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Biohaven by 160.7% in the 4th quarter. Wellington Management Group LLP now owns 634,055 shares of the company's stock valued at $23,682,000 after purchasing an additional 390,888 shares in the last quarter. Finally, Emerald Advisers LLC acquired a new stake in shares of Biohaven during the 4th quarter worth about $13,466,000. 88.78% of the stock is owned by hedge funds and other institutional investors.

Biohaven Trading Up 1.4 %

NYSE:BHVN traded up $0.31 during trading hours on Friday, hitting $22.76. The stock had a trading volume of 2,101,533 shares, compared to its average volume of 1,155,605. The business has a 50 day simple moving average of $24.91 and a two-hundred day simple moving average of $36.58. Biohaven Ltd. has a 1-year low of $15.79 and a 1-year high of $55.70. The company has a market cap of $2.32 billion, a PE ratio of -2.43 and a beta of 1.33.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). Research analysts expect that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Insider Activity

In other news, Director John W. Childs bought 32,700 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was bought at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the transaction, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 16.00% of the company's stock.

Wall Street Analyst Weigh In

BHVN has been the topic of several recent analyst reports. Royal Bank of Canada reissued an "outperform" rating and set a $61.00 price objective on shares of Biohaven in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $54.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the company a "buy" rating in a research note on Thursday, March 20th. Morgan Stanley lowered their price target on Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 5th. Fourteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Biohaven has a consensus rating of "Buy" and a consensus target price of $62.54.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.